Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

Abstract

In this analysis, ixekizumab is the most cost-efficient biologic in the US when targeting complete resolution, as measured by PASI 100 in PsO.

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab

“…For the previously reported SLR (data collected from January 1990 to November 2015, with an update from November 2015 to November 2016) the following databases were searched in Ovid: Embase, Ovid MEDLINE, Ovid MEDLINE Daily Update, Ovid MEDLINE In‐Process & Other Non‐Indexed Citations, PsycINFO, Econlit, ACP Journal Club, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Cochrane Methodology Register, Database of Abstracts of Reviews of Effects, Health Technology Assessment, NHS Economic Evaluation Database and Database of Abstracts of Reviews of Effects. This analysis was carried out for previously reported NMAs; of the seven secukinumab studies identified, five met the criteria for selection in this MAIC.…”

“…A comparison of long‐term efficacy and how this impacts long‐term quality of life is needed. The higher percentages of patients achieving clear or nearly clear skin may translate into greater cost‐efficiency, as a recently published analysis of FDA‐approved biologics found, at least based on U.S. pricing, monthly cost per additional PASI 100 responder was lowest in patients treated with ixekizumab vs. patients treated with secukinumab or other biologics …”

Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany

“…3). 43 This analysis is the first to demonstrate that secukinumab is economically beneficial, demonstrating the lowest costs per sustained PASI 90 responder up to 52 weeks compared with adalimumab, etanercept, infliximab and ustekinumab. Treatment sequences starting with secukinumab were also cost-efficient.…”

“…42 In the United States, Al Sawah et al 43 showed that secukinumab had the lowest monthly cost per additional PASI 90 responder ($15 603) compared with other Food and Drug Administration (FDA)-approved biologic treatments including ixekizumab, a recent humanized monoclonal antibody that neutralizes IL-17A. 43 This analysis is the first to demonstrate that secukinumab is economically beneficial, demonstrating the lowest costs per sustained PASI 90 responder up to 52 weeks compared with adalimumab, etanercept, infliximab and ustekinumab. This is of notable value to the payer, given the lifelong chronic nature of the disease and the need for continuous treatment.…”

“…Secukinumab had the lowest cost per PASI 90 responder over 16 and 52 weeks and cost per sustained PASI 90 response over 52 weeks compared with other biologic treatments (Fig. 42 In the United States, Al Sawah et al 43 showed that secukinumab had the lowest monthly cost per additional PASI 90 responder ($15 603) compared with other Food and Drug Administration (FDA)-approved biologic treatments including ixekizumab, a recent humanized monoclonal antibody that neutralizes IL-17A. 42 also demonstrated that secukinumab was associated with the lowest cost per PASI 90 responder (€31 801), followed by ustekinumab (€35 647) and infliximab (€46 103) over a 2-year period.…”